All News

2021

May

Two women discussing
Story / May 04, 2021

Fighting MS through innovation

Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).

Read More

April

Media Release / Apr 16, 2021

Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS

Read More

March

Media Release / Mar 30, 2021

Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis

Read More

February

Media Release / Feb 16, 2021

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Read More
Media Release / Feb 16, 2021

Novartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector pen

Read More

January

Media Release / Jan 29, 2021

Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

Read More
2020

December

Media Release / Dec 17, 2020

Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition

Read More

November

Media Release / Nov 02, 2020

Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention

Read More

October

Media Release / Oct 21, 2020

Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)

Read More

September

Media Release / Sep 11, 2020

Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More